this is Pavas Mehra here at Pareto
Securities' 10th annual health care
conference in Stockholm and with me I
have Martin Welschof CEO of BioInvent
a company listed on Stockholm First North.
Martin could you please tell us a little
bit more about BioInvent and the
products that you're working with. Yes so
BioInvent is obviously very interesting
company so we have a very nice portfolio
so we have focused around a portfolio
and a platform basically and at the core
of the company is that platform that
delivers multiple projects that were
using in one way for our partners such
as Pfizer but also building their own
product portfolio. Could you tell us a
little bit more about the collaborations
that you have with other companies such
as Pfizer.
Yeah, so we have a number of
collaborations so you know we have
collaboration also with Daiichi and we
have one with Takeda and Mitsubishi
Tanabe so they have already products all
of our antibody library that they're
moving into the clinic basically and
they do that on their own and whenever
they hit a milestone and we had some
money and with Pfizer we have currently
very active collaboration which is more
around the discovery of new targets and
antibodies and most recently we had very
important breakthrough which means we
discovered a target which then Pfizer
picked and selected in order to do for the work on it
And what is the market potential  in numbers regarding this specific product. Yeah, so regarding this specific produkt
it's difficult to give a number
because then first you have to do all
the clinical development etc but if you
look at the Pfizer deal so it's what
structure like this they provided an
upfront payment of three million they
did also an equity investment of six
million into the company and then total
milestones without royalties is up to five
hundred million U.S. dollars obviously
you know it's a long way to go that but
I think has a lot of potential it's a
great potential and
looking forward more like out of an
investor perspective both short term and medium term, are there any
specific events that the investor should
be on the lookout for. Yes, so I'm
expecting so we had the first milestone
with Pfizer and I'm expecting other ones so
stay tuned in this respect
then. Other like Big Pharma? Well in the
Pfizer collaboration itself. Okay. So
because we have a lot of momentum and
good progress and you know we think that
we should hit some other milestone soon
then as I said so we're also using our
platform to build our own portfolio so
we have now two clinical programs and
might structure some collaboration of
the second program that we're currently
discussing so there's also something
that might materialize during the second
half of this year so those are near-term
milestones basically an eventful end
to the year basically. Looking forward to
it. Thank you very much very much Martin Welschof
Thank you
